Healthcare provider profile · identity verified

Matthew J Wietrzykowski, MD

Allopathic & Osteopathic Physicians|Internal Medicine · HAMTRAMCK, MI · NPI 1528040979

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Matthew J Wietrzykowski, MD received $240.95 in general payments during 2025 across 12 reported records.

Novo Nordisk Inc accounted for 37.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 7 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$240.95

12 reported records · 6 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$90.37	37.5%	4	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$54.68	22.7%	3	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$46.31	19.2%	2	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$18.15	7.5%	1	2025
Cranial Technologies, Inc	Unresolved — no canonical attribution shown	$16.01	6.6%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$15.43	6.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$240.95	12

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$27.31	1	2025
Source payment records 2025-10-16 · Lilly USA, LLC · $27.31 · Open Payments source
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$22.15	1	2025
Source payment records 2025-10-28 · AstraZeneca Pharmaceuticals LP · $22.15 · Open Payments source
JARDIANCE Normalized: jardiance	Drug	Lilly USA, LLC	$19.00	1	2025
Source payment records 2025-09-21 · Lilly USA, LLC · $19.00 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$18.15	1	2025
Source payment records 2025-11-05 · PFIZER INC. · $18.15 · Open Payments source
ZAVZPRET Normalized: zavzpret	Drug	PFIZER INC.	$18.15	1	2025
Source payment records 2025-11-05 · PFIZER INC. · $18.15 · Open Payments source
Doc Band Normalized: doc band	Device	Cranial Technologies, Inc	$16.01	1	2025
Source payment records 2025-12-09 · Cranial Technologies, Inc · $16.01 · Open Payments source
Cologuard Collection Kit Normalized: cologuard collection kit	Device	Exact Sciences Corporation	$15.43	1	2025
Source payment records 2025-10-02 · Exact Sciences Corporation · $15.43 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	155	exact normalized	Medicare Part D
JARDIANCE jardiance	2025	Jardiance	2024	331	exact normalized	Medicare Part D
MOUNJARO mounjaro	2025	Mounjaro	2024	32 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	155	32
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	331	67
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	32	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	55	11
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	249	39
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	64	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1189	245
Omeprazole	Omeprazole	648	136
Lisinopril	Lisinopril	467	92
Amlodipine Besylate	Amlodipine Besylate	453	109
Losartan Potassium	Losartan Potassium	424	92
Metformin Hcl	Metformin Hcl	394	77
Jardiance	Empagliflozin	331	67
Levothyroxine Sodium	Levothyroxine Sodium	313	52
Albuterol Sulfate Hfa	Albuterol Sulfate	300	55
Metformin Hcl Er	Metformin Hcl	279	61
Ozempic	Semaglutide	249	39
Pravastatin Sodium	Pravastatin Sodium	244	49
Gabapentin	Gabapentin	241	52
Metoprolol Tartrate	Metoprolol Tartrate	240	49
Fluticasone Propionate	Fluticasone Propionate	221	59
Metoprolol Succinate	Metoprolol Succinate	220	45
Hydrochlorothiazide	Hydrochlorothiazide	205	41
Tamsulosin Hcl	Tamsulosin Hcl	204	51
Alprazolam	Alprazolam	195	33
Carvedilol	Carvedilol	193	46
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	190	53
Pantoprazole Sodium	Pantoprazole Sodium	179	33
Clopidogrel	Clopidogrel Bisulfate	174	37
Rosuvastatin Calcium	Rosuvastatin Calcium	169	35
Triamcinolone Acetonide	Triamcinolone Acetonide	169	42
Famotidine	Famotidine	166	32
Farxiga	Dapagliflozin Propanediol	155	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	151	29
Betamethasone Valerate	Betamethasone Valerate	150	38
Januvia	Sitagliptin Phosphate	139	25
Diclofenac Sodium	Diclofenac Sodium	138	27
Simvastatin	Simvastatin	137	25
Alcohol Prep Pads	Alcohol Antiseptic Pads	135	29
Nifedipine Er	Nifedipine	135	30
Ketoconazole	Ketoconazole	131	30
Tizanidine Hcl	Tizanidine Hcl	130	38
Carbidopa-Levodopa	Carbidopa/Levodopa	124	25
Furosemide	Furosemide	122	29
Alendronate Sodium	Alendronate Sodium	121	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	113	27
Trazodone Hcl	Trazodone Hcl	113	24
Acetaminophen-Codeine	Acetaminophen With Codeine	96	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	95	28
Duloxetine Hcl	Duloxetine Hcl	91	16
Clonazepam	Clonazepam	88	13
Allopurinol	Allopurinol	85	17
Glipizide Er	Glipizide	85	14
Tramadol Hcl	Tramadol Hcl	81	18
Ammonium Lactate	Ammonium Lactate	80	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	77	17
Ipratropium Bromide	Ipratropium Bromide	72	18
Venlafaxine Hcl Er	Venlafaxine Hcl	68	11
Amitriptyline Hcl	Amitriptyline Hcl	67	12
Doxycycline Monohydrate	Doxycycline Monohydrate	67	56
Glimepiride	Glimepiride	67	13
Vascepa	Icosapent Ethyl	67	11
Ventolin Hfa	Albuterol Sulfate	67	17
Eliquis	Apixaban	64	17
Atenolol	Atenolol	62	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	62	20
Pioglitazone Hcl	Pioglitazone Hcl	61	17
Diazepam	Diazepam	58	11
Potassium Chloride	Potassium Chloride	57	16
Pregabalin	Pregabalin	56	suppressed
Trulicity	Dulaglutide	55	11
Quetiapine Fumarate	Quetiapine Fumarate	53	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	52	suppressed
Montelukast Sodium	Montelukast Sodium	50	suppressed
Xarelto	Rivaroxaban	50	suppressed
Lorazepam	Lorazepam	49	suppressed
Nitroglycerin	Nitroglycerin	49	11
Mirtazapine	Mirtazapine	48	suppressed
Sertraline Hcl	Sertraline Hcl	48	14
Hydralazine Hcl	Hydralazine Hcl	46	14
Verapamil Er	Verapamil Hcl	46	suppressed
Prednisone	Prednisone	45	28
Levetiracetam	Levetiracetam	44	suppressed
Novolog Flexpen	Insulin Aspart	44	11
Comfort Ez Pen Needle	Pen Needle, Diabetic	42	12
Meclizine Hcl	Meclizine Hcl	42	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	42	suppressed
Ondansetron Odt	Ondansetron	39	11
Single Use Swab	Alcohol Antiseptic Pads	39	15
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Acarbose	Acarbose	37	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	37	33
Finasteride	Finasteride	37	suppressed
Ondansetron Hcl	Ondansetron Hcl	37	suppressed
Enalapril Maleate	Enalapril Maleate	36	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	36	19
Lidocaine	Lidocaine	35	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Topiramate	Topiramate	34	suppressed
Entresto	Sacubitril/Valsartan	33	suppressed
Azithromycin	Azithromycin	32	18
Baclofen	Baclofen	32	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Mounjaro	Tirzepatide	32	suppressed
Clobetasol Propionate	Clobetasol Propionate	31	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	suppressed
Chlorthalidone	Chlorthalidone	30	suppressed
Ranolazine Er	Ranolazine	30	suppressed
Spironolactone	Spironolactone	29	suppressed
Incruse Ellipta	Umeclidinium Bromide	28	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	11
Clonidine Hcl	Clonidine Hcl	27	suppressed
Aliskiren	Aliskiren Hemifumarate	26	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	25	suppressed
Linzess	Linaclotide	25	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	23	suppressed
Repaglinide	Repaglinide	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Metronidazole	Metronidazole	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Breyna	Budesonide/Formoterol Fumarate	20	suppressed
Bydureon Bcise	Exenatide Microspheres	20	suppressed
Colchicine	Colchicine	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Naproxen	Naproxen	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	15
Tradjenta	Linagliptin	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	17	suppressed
Clotrimazole	Clotrimazole	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Nystatin	Nystatin	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Topamax	Topiramate	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Mometasone Furoate	Mometasone Furoate	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Icosapent Ethyl	Icosapent Ethyl	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	15	12
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Brilinta	Ticagrelor	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Roflumilast	Roflumilast	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Crestor	Rosuvastatin Calcium	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Glipizide	Glipizide	13	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	13	suppressed
M-Natal Plus	Pnv,calcium 72/Iron/Folic Acid	13	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	13	suppressed
Victoza 2-Pak	Liraglutide	13	suppressed
Amiloride Hcl	Amiloride Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Risperidone	Risperidone	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	11	suppressed
Atrovent Hfa	Ipratropium Bromide	11	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Methylprednisolone	Methylprednisolone	11	11
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$240.95 · 12 records	Novo Nordisk Inc	Cologuard Collection Kit, Doc Band, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, ZAVZPRET	9	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error